A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: A comparative cost-effectiveness analysis between international guidelines

Gastrointestinal Endoscopy

Volumn 80, Issue 5, 2014, Pages 842-848

  Lutgens, Maurice ^a,b   Van Oijen, Martijn ^a,b,c   Mooiweer, Erik ^a   Van Der Valk, Mirthe ^a   Vleggaar, Frank ^a   Siersema, Peter ^a   Oldenburg, Bas ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Dutch Initiative on Crohn and Colitis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COLONOSCOPY; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SURVEILLANCE; DYSPLASIA; HIDDEN MARKOV MODEL; HIGH RISK POPULATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDICAL CARE; PRIORITY JOURNAL; PROCTOCOLECTOMY; QUALITY ADJUSTED LIFE YEAR; REGIONAL METASTASIS; CARCINOMA; COLORECTAL NEOPLASMS; COMPLICATION; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; GASTROENTEROLOGY; PRACTICE GUIDELINE; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; UNITED KINGDOM; UNITED STATES;

ADULT; CARCINOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; GASTROENTEROLOGY; GREAT BRITAIN; HUMANS; INFLAMMATORY BOWEL DISEASES; MARKOV CHAINS; MODELS, ECONOMIC; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; UNITED STATES;

EID: 84927794799     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2014.02.1031     Document Type: Article

References (26)

1. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738-45.
2. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
3. Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995;109:1188-96.
4. Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000;46:500-6.
5. Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc 2009;69:1299-310.
6. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009;104:2222-32.
7. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(Suppl 5):10-2.
8. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124:544-60.
9. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140: 1785-94.
10. US Census Life Tables, 2012. Available at: http://www.census.gov/compendia/statab/cats/births-deaths-marriages-divorces/life-expectancy.html. Accessed September 30, 2013.
11. Mooiweer E, Oldenburg B, Siersema PD. Implementation of the new British guidelines for colorectal cancer surveillance in extensive colitis: effects on neoplasia yield and colonoscopic workload. Inflamm Bowel Dis 2013;19:2603-10.
12. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25:657-68.
13. Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003;52:1127-32.
14. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228-35.
15. Hoyert DL, Xu J. Deaths: preliminary data for 2011. 2012. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-06.pdf. Accessed Sept 30, 2013.
16. Teeuwen PH, Stommel MW, Bremers AJ, et al. Colectomy in patients with acute colitis: A systematic review. J Gastrointest Surg 2009;13:676-86.
17. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis. Gastrointest Endosc 2002;56:48-54.
18. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-62.
19. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813-6.
20. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006;130:1941-9.
21. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-8.
22. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
23. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-8.
24. Holubar SD, Long KH, Loftus EV Jr, et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: A population-based study in Olmsted County, Minnesota. Dis Colon Rectum 2009;52:1815-23.
25. Loftus EV Jr, Friedman HS, Delgado DJ, et al. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis 2009;15:566-75.
26. Lutgens MW, Van Oijen MG, Van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-99.